

**THE STOCK EXCHANGE OF HONG KONG LIMITED**  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)**APPENDIX 5****FORMS RELATING TO LISTING****FORM F****THE GROWTH ENTERPRISE MARKET (GEM)****COMPANY INFORMATION SHEET****Case Number: 20130402-I12021-0001**

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this information sheet, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this information sheet.

**Company name:** New Ray Medicine International Holding Limited**Stock code (ordinary shares):** 8180

This information sheet contains certain particulars concerning the above company (the "Company") which is listed on the Growth Enterprise Market ("GEM") of the Stock Exchange of Hong Kong Limited (the "Exchange"). These particulars are provided for the purpose of giving information to the public with regard to the Company in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of The Stock Exchange of Hong Kong Limited (the "GEM Listing Rules"). They will be displayed at the GEM website on the Internet. This information sheet does not purport to be a complete summary of information relevant to the Company and/or its securities.

The information in this sheet was updated as of .....24 October 2013.....

**A. General**Place of incorporation: BermudaDate of initial listing on GEM: 25 October 2013Name of Sponsor(s): Kingsway Capital LimitedNames of directors: *Executive Directors:*  
(please distinguish the status of the directors  
- Executive, Non-Executive or Independent  
Non-Executive) Zhou Ling  
Dai Haidong  
Yang Fang  
Lee Chik Yuet*Independent non-executive Directors:*  
Leung Chi Kin  
Ho Hau Cheung  
Sung Hak Keung, Andy

**THE STOCK EXCHANGE OF HONG KONG LIMITED**  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Name(s) of substantial shareholder(s):  
(as such term is defined in rule 1.01 of the GEM Listing Rules) and their respective interests in the ordinary shares and other securities of the Company

	Number of shares	Approximate percentage of shareholding
Town Health Pharmaceutical Limited ( <i>Note 1</i> )	249,600,000	31.20%
Town Health (BVI) Limited ( <i>Note 1</i> )	249,600,000	31.20%
Town Health International Investments Limited ( <i>Note 1</i> )	249,600,000	31.20%
Mr. Zhou Ling ( <i>Note 2</i> )	147,160,000	18.40%
Ms. Yang Fang ( <i>Note 2</i> )	147,160,000	18.40%

Note:

1. Town Health Pharmaceutical Limited is wholly-owned by Town Health (BVI) Limited, which is in turn wholly-owned by Town Health International Investments Limited. Accordingly, Town Health International Investment Limited and Town Health (BVI) Limited are deemed to be interested in all the 249,600,000 shares of the Company held by Town Health Pharmaceutical Limited by virtue of the Securities and Futures Ordinance (Chapter 571 of the laws of Hong Kong).
2. Mr. Zhou Ling and Ms. Yang Fang, being husband and wife, are deemed to be interested in all the 147,160,000 Shares, which comprise 104,396,190 Shares and 42,763,810 Shares held by Mr. Zhou Ling and Ms. Yang Fang respectively.

Name(s) of company(ies) listed on GEM or the Main Board of the Stock Exchange within the same group as the Company: N/A

Financial year end date: 31 December

Registered address: Clarendon House  
2 Church Street  
Hamilton HM 11  
Bermuda

Head office and principal place of business: Room 3702-03  
Dikai International Centre  
Hangzhou City  
Zhejiang Province  
People's Republic of China

Web-site address (if applicable): [www.newraymedicine.com](http://www.newraymedicine.com)

Share registrar: Tricor Investor Services Limited

Auditors: Deloitte Touche Tohmatsu

**B. Business activities**

(Please insert here a brief description of the business activities undertaken by the Company and its subsidiaries.)

The Company and its subsidiaries are principally engaged in pharmaceutical distribution business in the People's Republic of China.

**C. Ordinary shares**

Number of ordinary shares in issue: 800,000,000

**THE STOCK EXCHANGE OF HONG KONG LIMITED**  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Par value of ordinary shares in issue: HK\$0.01 per share

Board lot size (in number of shares): 8,000

Name of other stock exchange(s) on which ordinary shares are also listed: N/A

**D. Warrants**

Stock code: N/A

Board lot size: N/A

Expiry date: N/A

Exercise price: N/A

Conversion ratio: N/A  
(Not applicable if the warrant is denominated in dollar value of conversion right)

No. of warrants outstanding: N/A

No. of shares falling to be issued upon the exercise of outstanding warrants: N/A

**E. Other securities**

Details of any other securities in issue.  
(i.e. other than the ordinary shares described in C above and warrants described in D above but including options granted to executives and/or employees).

(Please include details of stock code if listed on GEM or the Main Board or the name of any other stock exchange(s) on which such securities are listed).

If there are any debt securities in issue that are guaranteed, please indicate name of guarantor.

N/A

**Responsibility statement**

The directors of the Company (the “Directors”) as at the date hereof hereby collectively and individually accept full responsibility for the accuracy of the information contained in this information sheet (“the Information”) and confirm, having made all reasonable inquiries, that to the best of their knowledge and belief the Information is accurate and complete in all material respects and not misleading or deceptive and that there are no other matters the omission of which would make any Information inaccurate or misleading.

The Directors also collectively and individually accept full responsibility for submitting a revised information sheet, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.

The Directors acknowledge that the Stock Exchange has no responsibility whatsoever with regard to the Information and undertake to indemnify the Exchange against all liability incurred and all losses suffered by the Exchange in connection with or relating to the Information.

**THE STOCK EXCHANGE OF HONG KONG LIMITED**  
(A wholly-owned subsidiary of Hong Kong Exchanges and Clearing Limited)

Signed:

\_\_\_\_\_  
Zhou Ling

\_\_\_\_\_  
Dai Haidong

\_\_\_\_\_  
Yang Fang

\_\_\_\_\_  
Lee Chik Yuet

\_\_\_\_\_  
Leung Chi Kin

\_\_\_\_\_  
Ho Hau Cheung

\_\_\_\_\_  
Sung Hak Keung, Andy

**NOTES**

- (1) *This information sheet must be signed by or pursuant to a power of attorney for and on behalf of each of the Directors of the Company.*
- (2) *Pursuant to rule 17.52 of the GEM Listing Rules, the Company must submit to the Exchange (in the electronic format specified by the Exchange from time to time) for publication on the GEM website a revised information sheet, together with a hard copy duly signed by or on behalf of each of the Directors, as soon as reasonably practicable after any particulars on the form previously published cease to be accurate.*
- (3) *Please send a copy of this form by facsimile transaction to Hong Kong Securities Clearing Company Limited (on 2815-9353) or such other number as may be prescribed from time to time) at the same time as the original is submitted to the Exchange.*